Document Detail

Blackberry-induced hand-foot skin reaction to sunitinib.
MedLine Citation:
PMID:  18998055     Owner:  NLM     Status:  MEDLINE    
Sunitinib is an orally administered small molecule that was approved by the US Food and Drug Administration in January 2006 as monotherapy for the treatment of patients with advanced renal cell carcinoma (RCC) and patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. Data pooled from multiple sunitinib dose-escalation trials showed that sunitinib is associated with various adverse events, with HFSR occurring in up to 20% of patients. We describe a 48-year-old woman with a history of metastatic colorectal cancer treated with single-agent sunitinib who developed pain and tenderness in areas of friction secondary to Blackberry use, and was diagnosed with trauma-induced hand-foot skin reaction (HFSR) secondary to sunitinib therapy.
Susan L Boone; Gayle Jameson; Daniel Von Hoff; Mario E Lacouture
Related Documents :
8697395 - Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor ...
2543225 - Rhabdoid tumor of kidney. a report of 111 cases from the national wilms' tumor study pa...
3944885 - The adrenal gland and renal cell carcinoma: is ipsilateral adrenalectomy a necessary co...
8583595 - Long-term outcome after percutaneous treatment of transitional cell carcinoma of the re...
8931685 - Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyng...
21134765 - Controversies in loco-regional treatment: post-mastectomy radiation for pt2-pt3n0 breas...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-11-08
Journal Detail:
Title:  Investigational new drugs     Volume:  27     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-06-25     Completed Date:  2009-09-30     Revised Date:  2009-10-05    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  389-90     Citation Subset:  IM    
Department of Dermatology, Northwestern University's Feinberg School of Medicine, Chicago, IL 60611, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*
Cellular Phone*
Colorectal Neoplasms / drug therapy
Drug Eruptions / etiology
Foot Dermatoses / etiology
Hand Dermatoses / etiology
Indoles / adverse effects*
Middle Aged
Pyrroles / adverse effects*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Indoles; 0/Pyrroles; 0/sunitinib
Erratum In:
Invest New Drugs. 2009 Aug;27(4):391

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detection of early liver fibrosis in patients with intestinal schistosomiasis: sonographic and histo...
Next Document:  Expression of HIF-1, galectin-3, cox-2 and Wilms tumor-1 protein in multiple schwannomas of the conu...